Stephanie Schorge

Last updated
Stephanie Schorge
Alma mater
Scientific career
Institutions University College London
Thesis mRNA variants of the n-type Ca channel α₁B subunit : their distribution and functional impact on the mammalian nervous system  (1999)

Stephanie Schorge is a Professor of Neuroscience in the Department of Neuroscience, Physiology and Pharmacology at University College London. She is known for her research into mutations that cause neurological diseases.

Contents

Education and career

Schorge received her B.S. from Yale University in 1994. [1] She obtained a Ph.D. in Neuroscience from Brown University [2] where she worked with Diane Lipscombe. Schorge has held postdoctoral positions at the Department of Pharmacology and the Institute of Neurology, both at the University College London. [3] She has had a fellowship from the Worshipful Company of Pewterers [4] and a university research fellowship from the Royal Society. [5] In 2018 Schorge moved to the UCL School of Pharmacy to become professor in translational neuroscience and director of the research department of pharmacology. [4] In 2021 she became head of the Department of Neuroscience, Physiology and Pharmacology (NPP). [1] She was subsequently awarded the Sophia Jex-Blake Chair of Physiology.

Research

Schorge is known for her research in how mutations in ion channels can cause neurological disease and how manipulating ion channels can be used to treat disease. She has worked on RNA processing in voltage gated calcium channels, [6] [7] single channel biophysics of NMDA receptors. [8] [9] and investigated the functional impacts of mutations in ion channels that are linked to human neurological disorders, the channelopathies. [10] She has also examined the genetics and functions of mutations linked to epilepsy, particularly in sodium channels, [11] and researched gene therapy treatments for epilepsy. [12]

Selected publications

References

  1. 1 2 UCL (2021-07-12). "Prof Stephanie Schorge". UCL Division of Biosciences. Retrieved 2022-01-06.
  2. ↑ "ORCID". orcid.org. Retrieved 2022-01-06.
  3. ↑ Admin, ERUK (2019-05-09). "Stephanie Schorge | Epilepsy Research UK". epilepsyresearch.org.uk. Retrieved 2022-01-06.
  4. 1 2 "Iris View Profile". iris.ucl.ac.uk. Retrieved 2021-12-30.
  5. ↑ "Royal Society announces prestigious University Research Fellowships for 2010 | Royal Society". royalsociety.org. Retrieved 2023-04-09.
  6. ↑ Schorge, S.; Gupta, S.; Lin, Z.; McEnery, M. W.; Lipscombe, D. (1999-09-02). "Calcium channel activation stabilizes a neuronal calcium channel mRNA". Nature Neuroscience. 2 (9): 785–790. doi:10.1038/12153. ISSN   1097-6256. PMID   10461216. S2CID   11155519.
  7. ↑ Lin, Z.; Lin, Y.; Schorge, S.; Pan, J. Q.; Beierlein, M.; Lipscombe, D. (1999-07-01). "Alternative splicing of a short cassette exon in alpha1B generates functionally distinct N-type calcium channels in central and peripheral neurons". The Journal of Neuroscience. 19 (13): 5322–5331. doi:10.1523/JNEUROSCI.19-13-05322.1999. ISSN   0270-6474. PMC   6782300 . PMID   10377343.
  8. ↑ Schorge, Stephanie; Elenes, Sergio; Colquhoun, David (2005-12-01). "Maximum likelihood fitting of single channel NMDA activity with a mechanism composed of independent dimers of subunits". The Journal of Physiology. 569 (Pt 2): 395–418. doi:10.1113/jphysiol.2005.095349. ISSN   0022-3751. PMC   1464248 . PMID   16223763.
  9. ↑ Schorge, Stephanie; Elenes, Sergio; Colquhoun, David (2005). "Maximum likelihood fitting of single channel NMDA activity with a mechanism composed of independent dimers of subunits". The Journal of Physiology. 569 (2): 395–418. doi:10.1113/jphysiol.2005.095349. ISSN   1469-7793. PMC   1464248 . PMID   16223763.
  10. ↑ Schorge, Stephanie (2018-02-14). "Channelopathies go above and beyond the channels" (PDF). Neuropharmacology. 132: 1–2. doi:10.1016/j.neuropharm.2018.02.011. ISSN   1873-7064. PMID   29454019. S2CID   3518363.
  11. ↑ Tate, Sarah K.; Depondt, Chantal; Sisodiya, Sanjay M.; Cavalleri, Gianpiero L.; Schorge, Stephanie; Soranzo, Nicole; Thom, Maria; Sen, Arjune; Shorvon, Simon D.; Sander, Josemir W.; Wood, Nicholas W. (2005-04-12). "Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin". Proceedings of the National Academy of Sciences of the United States of America. 102 (15): 5507–5512. Bibcode:2005PNAS..102.5507T. doi: 10.1073/pnas.0407346102 . ISSN   0027-8424. PMC   556232 . PMID   15805193.
  12. ↑ Wykes, Robert C.; Heeroma, Joost H.; Mantoan, Laura; Zheng, Kaiyu; MacDonald, Douglas C.; Deisseroth, Karl; Hashemi, Kevan S.; Walker, Matthew C.; Schorge, Stephanie; Kullmann, Dimitri M. (2012-11-21). "Optogenetic and Potassium Channel Gene Therapy in a Rodent Model of Focal Neocortical Epilepsy". Science Translational Medicine. 4 (161): 161ra152. doi:10.1126/scitranslmed.3004190. PMC   3605784 . PMID   23147003.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.